JAMES F. YOUNG, PhD APPOINTED EXECUTIVE CHAIRMAN OF TECHIMMUNE JAMES F. YOUNG, PhD APPOINTED EXECUTIVE CHAIRMAN OF TECHIMMUNE
  • Home
  • About Us
  • Technology
  • News
    • Media Coverage
    • Press Releases
  • Contact Us
Menu
  • Home
  • About Us
  • Technology
  • News
    • Media Coverage
    • Press Releases
  • Contact Us

Press Releases

JAMES F. YOUNG, PhD APPOINTED EXECUTIVE CHAIRMAN OF TECHIMMUNE

JAMES F. YOUNG, PhD

Executive Chairman of TechImmune, effective August 1,2025.

Dr. Young brings an extraordinary depth of experience in vaccine science, immunology, and pharmaceutical development, with more than 40 years of leadership across academia, government initiatives, and the biotechnology industry. He has been a driving force in advancing vaccine innovation, regulatory strategy, and global health impact.

He was involved in the Operation Warp Speed effort, the U.S. government’s coordinated initiative to accelerate the development, manufacturing, and distribution ofCOVID-19 vaccines during the height of the pandemic. He served as the Novavax Board of Directors Chairman in from 2011, until March of this year as the company emerged as a leading innovator with the development of Nuvaxovid, the only protein-based SARS CoV-2 vaccine marketed worldwide. Prior to Novavax, he served as President of Research and Development at MedImmune, where he oversaw the development of multiple products including, FluMist, the first intranasal influenza vaccine and Synagis to prevent respiratory synticial virus disease which was the first monoclonal antibody marketed for an infectious disease.

In 2005, he was honored with the Albert B. Sabin Humanitarian Award in recognition of his contributions to public health. Earlier in his career, Dr. Young helped establish and lead the Department of Molecular Genetics at SmithKline and French Laboratories (now part of GlaxoSmithKline) and served as a faculty member in the Department of Microbiology at Mount Sinai School of Medicine in New York City.

He holds a Bachelor of Science degrees in Biology and General Sciences from Villanova University and earned his Ph.D. in Microbiology and Immunology from Baylor College of Medicine in Houston, Texas. His expertise, vision, and unwavering commitment to medical innovation will be instrumental as TechImmune advances its mission to deliver transformative solutions for Long COVID and other immune-mediated conditions.

Please join us in welcoming Dr. James Young to TechImmune.

TECHIMMUNE was formed in 2021 and is developing a treatment for Long COVID- a medically urgent condition affecting over 10 million Americans for which no FDA-therapies currently exist. Using technology invented by Dr. Lbachir BenMohamed, a professor at University California, Irvine, the project has been a joint UCI-TechImmune effort, with animal model results meeting our initial expectations. We are now preparing to bring this program to the clinical testing stage. We believe our proven technology platform offers a novel immunological approach to this critical unmet medical need.

Read More

Recent Posts

  • JAMES F. YOUNG, PhD APPOINTED EXECUTIVE CHAIRMAN OF TECHIMMUNEAugust 1, 2025
  • BMC Public Health – “Prevalence of and factors associated with Long COVID among US adults: a nationwide survey”May 13, 2025
  • CIDRAP – “Studies: 1 in 7 US working-age adults report Long COVID, with heaviest burden on the poor”April 9, 2025
  • ABC News – “5 years ago, the WHO declared COVID a pandemic. Here’s a look at the disease by the numbers”March 11, 2025
  • World Health Organization – “Post COVID‑19 condition (Long COVID)”February 26, 2025
© 2022 TechImmune, LLC. All rights reserved.
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
  • Disclaimer
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}